BR112018075615A2 - compostos químicos - Google Patents
compostos químicosInfo
- Publication number
- BR112018075615A2 BR112018075615A2 BR112018075615A BR112018075615A BR112018075615A2 BR 112018075615 A2 BR112018075615 A2 BR 112018075615A2 BR 112018075615 A BR112018075615 A BR 112018075615A BR 112018075615 A BR112018075615 A BR 112018075615A BR 112018075615 A2 BR112018075615 A2 BR 112018075615A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- chronic
- compound
- diseases
- acute
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000001154 acute effect Effects 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000037361 pathway Effects 0.000 abstract 3
- 230000001684 chronic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 abstract 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 abstract 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000017004 dementia pugilistica Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 abstract 1
- 150000003235 pyrrolidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 230000004906 unfolded protein response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
a invenção refere-se a derivados de pirrolidina substituídos. especificamente, a invenção refere-se a compostos de acordo com a fórmula iii: em que a, b, l1, l2, l3, r1, r2, r3, r4, r5, r6, r9, r10, r30, y1, y2, z2, z4, z5 e z6 são como aqui definidos, e sais dos mesmos. os compostos da invenção são inibidores da via atf4 e podem ser úteis no tratamento de câncer, síndromes pré-cancerosas e doenças associadas a vias de resposta de proteína desdobradas ativadas, tais como doença de alzheimer, lesão da medula espinhal, lesão cerebral traumática, acidente vascular cerebral isquêmico, acidente vascular cerebral, diabetes, doença de parkinson, doença de huntington, doença de creutzfeldt-jakob, e doenças priônicas relacionadas, paralisia supranuclear progressiva, esclerose lateral amiotrófica, infarto do miocárdio, doença cardiovascular, inflamação, fibrose, doenças crônicas e agudas do fígado, doenças crônicas e agudas do pulmão, doenças crônicas e agudas do rim, encefalopatia traumática crônica (cte), neurodegeneração, demência, comprometimento cognitivo, aterosclerose, doenças oculares, arritmias, no transplante de órgãos e no transporte de órgãos para transplante. desta maneira, a invenção é ainda direcionada a composições farmacêuticas compreendendo um composto da invenção. a invenção é ainda direcionada a métodos de inibição da via atf4 e tratamento de desordens associadas aos mesmos utilizando um composto da invenção ou uma composição farmacêutica compreendendo um composto da invenção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611019696 | 2016-06-08 | ||
| PCT/IB2017/053370 WO2017212423A1 (en) | 2016-06-08 | 2017-06-07 | Chemcical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018075615A2 true BR112018075615A2 (pt) | 2019-07-02 |
Family
ID=59101532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018075615A BR112018075615A2 (pt) | 2016-06-08 | 2017-06-07 | compostos químicos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10851053B2 (pt) |
| EP (1) | EP3468948A1 (pt) |
| JP (1) | JP2019521109A (pt) |
| KR (1) | KR20190015492A (pt) |
| CN (1) | CN109563034A (pt) |
| AU (1) | AU2017279027A1 (pt) |
| BR (1) | BR112018075615A2 (pt) |
| CA (1) | CA3026983A1 (pt) |
| RU (1) | RU2018146946A (pt) |
| WO (1) | WO2017212423A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3665156A4 (en) | 2017-08-09 | 2021-04-28 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS, AND PROCEDURES |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| SG11202005561XA (en) | 2017-12-13 | 2020-07-29 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| EP3762380B1 (en) | 2018-03-05 | 2021-12-15 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| US20210130308A1 (en) * | 2018-03-23 | 2021-05-06 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) * | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| KR20210021519A (ko) * | 2018-06-05 | 2021-02-26 | 프락시스 바이오테크 엘엘씨 | 통합 스트레스 반응 경로의 저해제 |
| WO2020031107A1 (en) * | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI877136B (zh) * | 2019-02-13 | 2025-03-21 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| AU2020226633B2 (en) * | 2019-02-19 | 2025-07-03 | Shangpharma Innovation Inc. | Nurr1 receptor modulators |
| KR20210134351A (ko) * | 2019-02-25 | 2021-11-09 | 프락시스 바이오테크 엘엘씨 | 통합 스트레스 반응 경로의 억제제 |
| EP3959198A1 (en) | 2019-04-23 | 2022-03-02 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| EA202192900A1 (ru) | 2019-04-23 | 2022-03-18 | Эвотек Интернешнл Гмбх | Модуляторы пути интегрированной реакции на стресс |
| WO2020252207A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| AU2021213289A1 (en) | 2020-01-28 | 2022-07-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| KR20220151635A (ko) | 2020-03-11 | 2022-11-15 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| EP4232153A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| EP4232447A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| EP4232154B1 (en) | 2020-10-22 | 2024-11-13 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| CN117062817A (zh) * | 2021-01-13 | 2023-11-14 | 斯瑞福治疗股份有限公司 | 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物 |
| CN116332818B (zh) * | 2021-12-22 | 2023-12-15 | 王喆明 | 四氢吡咯衍生物及其应用 |
| CN116751147A (zh) * | 2023-06-28 | 2023-09-15 | 深圳市茵诺圣生物科技有限公司 | 一种5-氨甲基-2-吡咯烷酮的合成方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| EP1179341B1 (en) * | 1999-05-18 | 2005-11-09 | Teijin Limited | Remedies or preventives for diseases in association with chemokines |
| DE60033530T2 (de) | 1999-08-24 | 2007-10-31 | Medarex Inc. | Humane antikörper gegen ctla-4 und deren verwendungen |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US6515013B2 (en) * | 2000-07-13 | 2003-02-04 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| JP2002105073A (ja) * | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
| ES2324981T3 (es) | 2000-12-21 | 2009-08-21 | Smithkline Beecham Corporation | Pirimidinaminas como moduladores de la angiogenesis. |
| SE0100326D0 (sv) | 2001-02-02 | 2001-02-02 | Astrazeneca Ab | New compounds |
| HRP20040805A2 (en) | 2002-03-13 | 2005-04-30 | Janssen Pharmaceutica N.V. | Carbonylamino derivatives as novel inhibitors histone deacetylase |
| SI2206517T1 (sl) | 2002-07-03 | 2023-12-29 | Ono Pharmaceutical Co., Ltd. | Imunopotencirni sestavki,ki obsegajo protitelesa proti PD-L1 |
| EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
| KR20050107399A (ko) | 2003-01-23 | 2005-11-11 | 오노 야꾸힝 고교 가부시키가이샤 | 인간 ｐｄ-1에 대하여 특이성을 갖는 물질 |
| WO2004071449A2 (en) * | 2003-02-12 | 2004-08-26 | Bristol-Myers Squibb Company | Lactams as modulators of chemokine receptor activity |
| EP1720545B1 (en) | 2004-03-03 | 2014-10-29 | ChemoCentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| CN101065385A (zh) * | 2004-07-22 | 2007-10-31 | 坎布里制药公司 | 治疗微生物感染的利福霉素衍生物 |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| CN103059138B (zh) | 2005-05-09 | 2015-10-28 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| ME02260B (me) | 2005-07-01 | 2016-02-29 | Medarex Inc | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| CN101678989A (zh) * | 2007-04-20 | 2010-03-24 | 因维斯塔技术有限公司 | 具有张力控制的紧凑连续的越端退纱（oeto)轴架 |
| WO2008150231A1 (en) | 2007-06-08 | 2008-12-11 | Astrazeneca Ab | New heterocyclic compounds for treatment of respiratory, airway or inflammatory disorders |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| JP2010095453A (ja) * | 2008-10-14 | 2010-04-30 | Kaneka Corp | 光学活性１−アリール−３−ピロリジノールの製造法 |
| MY188826A (en) | 2008-12-09 | 2022-01-06 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| CA2842364A1 (en) * | 2011-07-29 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| US9724413B2 (en) | 2011-08-01 | 2017-08-08 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors |
| JPWO2013065712A1 (ja) * | 2011-10-31 | 2015-04-02 | 東レ株式会社 | ジアザスピロウレア誘導体及びその医薬用途 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| JP5799117B2 (ja) * | 2013-02-05 | 2015-10-21 | 大日本住友製薬株式会社 | ウラシル誘導体からなる医薬 |
| CA2904794C (en) | 2013-03-15 | 2021-11-23 | Peter Walter | Modulators of the eif2alpha pathway |
| US20160318856A1 (en) * | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
| JP6577479B2 (ja) | 2014-02-27 | 2019-09-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用 |
-
2017
- 2017-06-07 WO PCT/IB2017/053370 patent/WO2017212423A1/en unknown
- 2017-06-07 EP EP17732235.1A patent/EP3468948A1/en not_active Withdrawn
- 2017-06-07 KR KR1020197000188A patent/KR20190015492A/ko not_active Withdrawn
- 2017-06-07 JP JP2018564292A patent/JP2019521109A/ja active Pending
- 2017-06-07 US US16/307,513 patent/US10851053B2/en not_active Expired - Fee Related
- 2017-06-07 CA CA3026983A patent/CA3026983A1/en not_active Abandoned
- 2017-06-07 CN CN201780045519.3A patent/CN109563034A/zh active Pending
- 2017-06-07 RU RU2018146946A patent/RU2018146946A/ru not_active Application Discontinuation
- 2017-06-07 AU AU2017279027A patent/AU2017279027A1/en not_active Abandoned
- 2017-06-07 BR BR112018075615A patent/BR112018075615A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA3026983A1 (en) | 2017-12-14 |
| US10851053B2 (en) | 2020-12-01 |
| RU2018146946A (ru) | 2020-07-10 |
| EP3468948A1 (en) | 2019-04-17 |
| KR20190015492A (ko) | 2019-02-13 |
| JP2019521109A (ja) | 2019-07-25 |
| AU2017279027A1 (en) | 2018-12-20 |
| WO2017212423A1 (en) | 2017-12-14 |
| CN109563034A (zh) | 2019-04-02 |
| US20190144384A1 (en) | 2019-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018075615A2 (pt) | compostos químicos | |
| BR112018075598A2 (pt) | compostos químicos | |
| BR112015012454A2 (pt) | compostos úteis como inibidores de atr cinase | |
| EA201290952A1 (ru) | Химические соединения | |
| BR112016028273A8 (pt) | derivados radiorrotulados de composto de 2-amino6-fluoro-n-[5-fluoro-piridin-3-il]-pirazol[1,5-a]pirimidin3-carboxamida úteis como inibidor de atr cinase, processo para preparação do referido composto, bem como diferentes formas sólidas do mesmo, uso destas, e composição farmacêutica | |
| NI200800024A (es) | Derivados de ciclohexilaminisoquinolona en calidad inhibidores de rho-quinasa | |
| CY1124828T1 (el) | Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης | |
| BR112012024380A2 (pt) | compostos químicos | |
| EA200900178A1 (ru) | Конденсированные гетероциклические производные и их применение | |
| EA201001159A1 (ru) | Конденсированные гетероциклические производные и их применение | |
| NI200800025A (es) | Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa | |
| UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
| EA200800975A1 (ru) | ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ | |
| BR0312398A (pt) | Derivado de 1,3-difenilprop-2-en-1-ona substituìdo, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituìdo | |
| NI201100099A (es) | Nuevos compuestos 578. | |
| CY1111323T1 (el) | Παραγωγα ισοκινολινης και ισοκινολινονης υποκατεστημενα με κυκλοαλκυλαμινες | |
| Peng et al. | Design, synthesis, and bioevaluation of benzamides: novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aβ aggregation, and β-secretase | |
| WO2008151288A3 (en) | Aromatic and heteroaromatic compounds useful in treating iron disorders | |
| WO2015056180A8 (en) | Indoline derivatives as inhibitors of perk | |
| EA033250B1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| WO2007041112A3 (en) | Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | |
| ZA202006439B (en) | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators | |
| BR112018073219A2 (pt) | Composto de fórmula i, composição farmacêutica, processo para síntese destescompostos e uso dos mesmos | |
| BRPI0506718A (pt) | compostos, processo de preparação dos mesmos, e, composição farmacêutica ou cosmética | |
| BR112019003174A2 (pt) | método para produzir derivados de 2-(3,6-di-halopiridin-2-il)-3h-imidazol[4,5-c]piridina e compostos relacionados pela reação do derivado de 3h-imidazol[4,5-c]piridina com uma base organometálica de zinco-amina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |